Clinical Management of Borderline Tumours of the Ovary – Experience from the “Berlin Online Tumour Conference for Gynaecological Malignancies” — Anticancer Research

Abstract

Borderline ovarian tumour (BOT) represents a rare and special tumour entity. Despite a generally favourable prognosis for patients with BOT, the presence of invasive peritoneal implants decreases the survival rate to 30-50%. In contrast to ovarian cancer, only few data exist concerning the current clinical management of patients with BOT. For this reason, the present analyses were performed for patients with BOT who were admitted into our online tumor conference for patients with gynaecological malignancies. Based on the results discussed in this article, the current aspects and problems regarding the diagnostic, surgical and conservative treatment and aftercare management of patients with BOT are considered.

NCI: Talking About Trials: Overcoming Bottlenecks in Clinical Communication (enrolment)

".......“Patient refusal rates may be less of a problem than low rates of trial offers,” wrote the authors."